FDA approves rivanetin as the first-line treatment for lung cancer.

Published Date: 08 Mar 2024

For NSCLCs with EGFR exon 20 insertion mutations, a bispecific medication receives complete approval.

Read Full News

Latest News

Rare Tumor in a Rare Location in Patient With Constipation

Could occupational exposure to sawdust explain this case?

ASTRO: American Society for Radiation Oncology

A Surgical First for Removal of an Appendiceal Neoplasm

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

What's Behind the Mysterious Chest Pain in Bladder Cancer Patient?

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

Cancer Deaths Fall, Cases Rise; Diabetes and Cancer Risk; Vitamin C for Cancer

— News, features, and commentary about cancer-related issues

Benign or Malignant? No Way to Tell Radiologically

Case shows importance of accurate preop diagnosis

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Todays Updates

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab

Deep TMS Reduces Suicidal Ideation by 70% in MDD, With Owen Muir, MD Owen Muir, MD, DFAACAP, FCTMSS

A secondary analysis found the SWIFT accelerated protocol eased suicidal ideation faster than standard daily deep TMS dosing in major depressive disorder.

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy Marco Meglio

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

This Week on NeurologyLive® — November 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show Marco Meglio, Jeffrey Cohen, MD

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

Latest News

Could occupational exposure to sawdust explain this case?

Technique deemed safe and feasible for selected patients and better than other minimally invasive approaches

Cardiomyopathy risks interrupting cancer treatment, worsening prognosis

— News, features, and commentary about cancer-related issues

Case shows importance of accurate preop diagnosis

News All Time

Blood Cancer's First New Drug in 29 Years; AI for Mammography? Phase III Myeloma Win

News, features, and commentary about cancer-related issues

More Evidence Ties Microplastics to Lung Cancer

Observational study shows greater microplastic burden in patients with lung malignancy

Nationwide Epinephrine Recall; FBI's Fauci Probe; Bruce Campbell's Cancer

Health news and commentary gathered by MedPage Today staff

9/11's Latest Wave of Cancers, 25 Years On

The health ramifications of the attack persist

Study Warns on Venetoclax in Double-Hit Lymphoma

Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen

Cancer Diagnosis, Then a Stroke; 9/11 Cancer Deaths; 'Grand Slam' Drug and Price

News, features, and commentary about cancer-related issues

Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC

Overall survival favored nivolumab-ipilimumab alone in LONESTAR trial

Significant Survival Boost With Novel ADCs in Relapsed Small-Cell Lung Cancer

Death risk cut by 54% with B7-H3-targeting tambotatug pelitecan and risvutatug rezetecan

No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy

Non-significant 4-month PFS increase with sacituzumab govitecan-pembrolizumab, no OS benefit

Cancer Drug Shortages Continue With No Immediate Path Toward Relief

All responding NCCN members reported shortages, priorities identified but solutions still needed

Brain MRI Surveillance Alone Helps Preserve Cognition in Small Cell Lung Cancer

Omitting prophylactic cranial irradiation led to improved cognitive failure-free survival

Nurse Accused of Exorcism; Death After 8 Hours of Plastic Surgery; Top Cancer Months

Health news and commentary gathered by MedPage Today staff

Novel Drug Cuts Risk for Death by 44% in Squamous Lung Cancer Trial

If approved, immunotherapy gotistobart could offer a chemo-free option in second-line setting

Unprecedented PFS in HER2-Mutant Lung Cancer, but With a Touch of Controversy

Practice-changing median of 14.3 months with T-DXd, but caution over early unfavorable OS trend

Drug Combo's Response Rates Top 90% in Small Cell Lung Cancer Trial

Bispecific antibody and ADC together impress in early study

ROS1-Targeting Lung Cancer Drug Yields 90% Response Rate

Early efficacy among the highest seen in lung cancer, expert says

Recommended News For You

An inadvertent loss of weight may be an indication to consult a physician, according to research.

Breast Density Laws Fall Short Raising Additional Screening

A study suggests that you should disregard the "pack-years" when determining your eligibility for lung cancer screening.

Single-dose radiation before surgery can eradicate breast cancer

According to a study, breast cancer in Syrian refugees tends to be diagnosed at an earlier stage and with more advanced tumors.

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

A Texas study found that the majority of pancreatic cancer patients do not receive life-saving surgery.

Recommended Articles For You

Oncology Treatment-Planning Simulation: Integrating Evidence, Technology, and Clinical Practice 

Hematopoietic Immune Microenvironment Plasticity: Mechanisms, Clinical Implications, and Emerging Therapeutics 

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape 

Understanding Bone Metastases: How Long Can Someone Live When Cancer Spreads To The Bones? 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA approves rivanetin as the first-line treatment for lung cancer.

2.

Combination treatment may help cut lifelong ibrutinib for chronic lymphocytic leukemia patients

3.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

4.

Discovery of estrogen receptor 'switches' may aid breast cancer treatment

5.

'Significant Milestone' for Radionuclide Therapy in Refractory Meningioma

1.

Virtual Oncology Follow-Up: Current Practices, Evidence, and Clinical Implications

2.

Clinical Pharmacology of Ferroptosis-Modulating Anticancer Pharmacotherapy

3.

Population Surveillance of Environmental Cancer Risk Clusters

4.

From Autoimmune Disorders to COVID-19: How Plasmapheresis Is Revolutionizing Modern Medicine 

5.

Therapeutic Advances in Tumor Calcium-Signaling Modulation

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII

3.

Screening for Red Cell Membrane Disorders Through Ektacytometry-Based Deformability Profiling

4.

Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

5.

Navigating the Complexities of Ph Negative ALL - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot